Glenmark Pharma gets ANDA nod for Clindamycin Phosphate Foam; Stock gains

Clindamycin Phosphate Foam is the generic version of Evoclin1 Foam, 1%, of Mylan Pharmaceuticals Inc.

Sep 21, 2021 10:09 IST India Infoline News Service

glenmark pharma
Glenmark Pharmaceuticals Ltd. (Glenmark) has received final approval by the United States Food & Drug Administration (USFDA) for Clindamycin Phosphate Foam, 1%, the generic version of Evoclin1 Foam, 1%, of Mylan Pharmaceuticals Inc.

According to IQVIATM sales data for the 12-month period ending July 2021, the Evoclin Foam, 1%, market achieved annual sales of approximately $12.0 million.

Glenmark’s current portfolio consists of 173 products authorized for distribution in the US marketplace and 47 ANDA’s pending approval with the USFDA.

In addition to these internal filings, Glenmark continues to identify and explore external develop.

At around 10.10 AM, Glenmark Pharmaceuticals Ltd was trading at Rs501.35 per piece up by Rs6.4 or 1.29% from its previous closing of Rs494.95 per piece on the BSE.

Related Story

Open Free Demat Account (Rs699)